Anna Glechner

Anna Glechner

Auto-generated profile, based on publicly available information

Anna Glechner

Department for Evidence-based Medicine and Evaluation, Danube University Krems, Krems, Austria

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Primary Care Diabetes
Verified
Journal Article
Open access
AGAnna Glechner
Anna Glechner
LKLina Keuchel
Lina Keuchel
LALisa Affengruber
Lisa Affengruber
VTViktoria Titscher
Viktoria Titscher
ISIsolde Sommer
Isolde Sommer
GGGerald Gartlehner
Gerald Gartlehner
To assess the efficacy, safety, and cost-effectiveness of lifestyle intervention, compared with treatment as usual in people with prediabetes as defined by the American Diabetes Association. For older studies, we used the 1985 World Health Organization definition. We systematically searched multiple electronic databases and referenced lists of pertinent review articles from January 1980 through November 2015. We performed an update search in MEDLINE on April 26, 2017. Based on a priori established eligibility criteria, we dually reviewed the literature, extracted data, and rated the risk of bias of included studies with validated checklists. To assess the efficacy of lifestyle intervention to prevent or delay further progression to type 2 diabetes, we conducted a random-effects meta-analysis. We assessed the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Pooled results of 16 randomized controlled trials showed that people with prediabetes who received lifestyle intervention had a lower rate of progression to type 2 diabetes after one (4% vs. 10%, RR 0.46 [CI 0.32, 0.66]) and three years of follow-up (14% vs. 23%, RR 0.64 [95% CI 0.53, 0.77]). The majority of the studies also showed a greater weight loss in lifestyle intervention participants, with a great variation between studies. Costs per quality-adjusted life-year were lower when the benefits of lifestyle intervention were analyzed over a lifelong time horizon compared to only the period of lifestyle intervention (three years) or to modeling over a ten-year period. Lifestyle intervention is an efficacious, safe, and cost-effective measure to reduce the risk of progression to type 2 diabetes in people diagnosed with prediabetes. More research is necessary to compare the efficacy of various modes, frequencies, and intensities of lifestyle intervention across studies.

1 March 2013 in European Journal of Cancer
Verified
Journal Article
Closed access
AGAnna Glechner
Anna Glechner
AWAchim Wöckel
Achim Wöckel
GGGerald Gartlehner
Gerald Gartlehner
KTKylie Thaler
Kylie Thaler
MSMichaela Strobelberger
Michaela Strobelberger
RKRolf Kreienberg
Rolf Kreienberg

3 December 2014 in Diabetologia
Verified
Journal Article
Closed access
PDF file
AGAnna Glechner
Anna Glechner
JHJürgen Harreiter
Jürgen Harreiter
GGGerald Gartlehner
Gerald Gartlehner
SRSonja Rohleder
Sonja Rohleder
AKAlexander Kautzky
Alexander Kautzky
Alexandra Kautzky-WillerAlexandra Kautzky-Willer
Alexandra Kautzky-Willer

31 March 2023 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
AGAnna Glechner
Anna Glechner
GWGernot Wagner
Gernot Wagner
JMJerzy W Mitus
Jerzy W Mitus
BTBirgit Teufer
Birgit Teufer
IKIrma Klerings
Irma Klerings
GGGerald Gartlehner
Gerald Gartlehner

23 February 2021 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
GWGernot Wagner
Gernot Wagner
DMDeddo Moertl
Deddo Moertl
AGAnna Glechner
Anna Glechner
VMVerena Mayr
Verena Mayr
IKIrma Klerings
Irma Klerings
Birgit WillingerBirgit Willinger
Birgit Willinger
Paracoccidioidomycosis is a systemic mycosis that is endemic in geographical regions of Central and South America. Cases that occur in nonendemic regions of the world are imported through migration and travel. Due to the limited number of cases in Europe, most physicians are not familiar with paracoccidioidomycosis and its close clinical and histopathological resemblance to other infectious and noninfectious disease. To increase awareness of this insidious mycosis, we conducted a systematic review to summarize the evidence on cases diagnosed and reported in Europe. We searched PubMed and Embase to identify cases of paracoccidioidomycosis diagnosed in European countries. In addition, we used Scopus for citation tracking and manually screened bibliographies of relevant articles. We conducted dual abstract and full-text screening of references yielded by our searches. To identify publications published prior to 1985, we used the previously published review by Ajello et al. Overall, we identified 83 cases of paracoccidioidomycosis diagnosed in 11 European countries, published in 68 articles. Age of patients ranged from 24 to 77 years; the majority were male. Time from leaving the endemic region and first occurrence of symptoms considerably varied. Our review illustrates the challenges of considering systemic mycosis in the differential diagnosis of people returning or immigrating to Europe from endemic areas. Travel history is important for diagnostic-workup, though it might be difficult to obtain due to possible long latency period of the disease.

24 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Gudrun Marie Ilse KreyeGudrun Marie Ilse Kreye
Gudrun Marie Ilse Kreye
MWManuela Wasl
Manuela Wasl
ADAndrea Dietz
Andrea Dietz
DKDaniela Klaffel
Daniela Klaffel
AGAndrea Groselj-Strele
Andrea Groselj-Strele
AGAnna Glechner
Anna Glechner
Aromatherapy is regularly used in the University Hospital Krems’s palliative care unit. In a retrospective analysis, we investigated whether there were improvements in nausea and vomiting in patients with advanced cancers over a time span of 24 months. Data collection used the medical records of patients who were institutionally approved to receive routine aroma applications for alleviating nausea and vomiting. The efficacy of using lemon oil pads was tested with one-dimensional chi-squared tests. Sixty-six patients received 222 applications of lemon oil on cotton pads; no data were available for 17 applications. The adequate relief of nausea and vomiting was reported for 149 (73%) applications, whereas no symptom control was seen for 56 (27%) applications. For the 56 applications without symptom control, first- and second-line rescue medications were successful in 53 and 3 cases, respectively. The use of aromatherapy with lemon oil pads against nausea and vomiting was feasible for 73% of all applications. All patients who did not benefit from aromatherapy had effective symptom control with a rescue medication. Large randomized prospective trials are necessary to evaluate the benefit of the use of lemon oil pads against nausea and vomiting in patients with advanced cancer.